No Benefit Seen for Revascularization Added to Drug Therapy in Carotid Stenosis
By Elana Gotkine HealthDay Reporter
FRIDAY, May 2, 2025 -- For patients with asymptomatic or symptomatic carotid stenosis of 50 percent or greater with a low or intermediate predicted stroke risk, there is no benefit for the addition of revascularization to optimized medical therapy (OMT) in the first two years, according to a study published in the May issue of The Lancet Neurology.
Simone J.A. Donners, M.D., from UMC Utrecht in the Netherlands, and colleagues examined whether patients with asymptomatic and symptomatic carotid stenosis with a low or intermediate predicted risk fir stroke, who received OMT, would benefit from additional revascularization in a multicenter randomized trial. Patients aged 18 years and older, with asymptomatic or symptomatic carotid stenosis of 50 percent or greater, and a five-year predicted risk for ipsilateral stroke of less than 20 percent, were randomly assigned to OMT alone or OMT plus revascularization (215 and 214 patients, respectively).
The researchers found that with respect to the primary hierarchical outcome composite of periprocedural death, fatal stroke, or fatal myocardial infarction; nonfatal stroke; nonfatal myocardial infarction; or new silent cerebral infarction on imaging assessed two years after randomization, no benefit was recorded in favor of either treatment group, with 11.4 and 11.3 percent wins for the OMT alone and OMT plus revascularization groups, and 77.3 percent ties between groups.
"We cannot rule out the possibility that revascularization will provide a small to moderate benefit in our patients beyond two years. We are, therefore, continuing follow-up to five years after randomization," the authors write.
Several authors disclosed ties to the biotechnology, publishing, and medico-legal industries.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Intravenous Tenecteplase Beneficial Before Endovascular Thrombectomy
FRIDAY, May 23, 2025 -- For patients with acute ischemic stroke due to large-vessel occlusion who present within 4.5 hours, intravenous tenecteplase before endovascular...
Pathological Fatigue Common Up to 12 Months After TIA
WEDNESDAY, May 14, 2025 -- Pathological fatigue is common up to 12 months after a diagnosis of transient ischemic attack (TIA), according to a study published online May 14 in...
Early Combination of Lipid-Lowering Therapy Beneficial After Myocardial Infarction
MONDAY, April 28, 2025 -- For patients with myocardial infarction (MI), early oral combination lipid-lowering therapy (LLT) is beneficial, according to a study published online in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.